NCOA5

Summary

NCOA5 (nuclear receptor coactivator 5, HGNC:15909) is a protein-coding gene on chromosome 20q13.12, encoding Nuclear receptor coactivator 5 (Q9HCD5). Nuclear receptor coregulator that can have both coactivator and corepressor functions.

This gene encodes a coregulator for the alpha and beta estrogen receptors and the orphan nuclear receptor NR1D2. The protein localizes to the nucleus, and is thought to have both coactivator and corepressor functions. Its interaction with nuclear receptors is independent of the AF2 domain on the receptors, which is known to regulate interaction with other coreceptors. Several alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 57727 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 104 total
• MANE Select transcript: NM_020967

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15909
Approved symbol	NCOA5
Name	nuclear receptor coactivator 5
Location	20q13.12
Locus type	gene with protein product
Status	Approved
Aliases	bA465L10.6, CIA
Ensembl gene	ENSG00000124160
Ensembl biotype	protein_coding
OMIM	616825
Entrez	57727

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000290231, ENST00000372291, ENST00000851082, ENST00000870777, ENST00000934594, ENST00000934595, ENST00000968230

RefSeq mRNA: 5 — MANE Select: NM_020967 NM_001348148, NM_001348149, NM_001348150, NM_001348151, NM_020967

CCDS: CCDS13392

Canonical transcript exons

ENST00000290231 — 8 exons

Exon	Start	End
ENSE00000662541	46068502	46068638
ENSE00001672871	46065029	46065228
ENSE00001753187	46079387	46079453
ENSE00003476758	46070210	46070536
ENSE00003784743	46067055	46067181
ENSE00003843208	46089817	46089962
ENSE00004283663	46060991	46062889
ENSE00004283664	46063360	46063680

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 97.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.0760 / max 341.1447, expressed in 1807 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187538	27.0760	1807

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	97.16	gold quality
ileal mucosa	UBERON:0000331	91.56	gold quality
cortical plate	UBERON:0005343	91.54	gold quality
ganglionic eminence	UBERON:0004023	91.23	gold quality
embryo	UBERON:0000922	91.22	gold quality
ventricular zone	UBERON:0003053	90.81	gold quality
calcaneal tendon	UBERON:0003701	90.70	gold quality
granulocyte	CL:0000094	90.14	gold quality
sural nerve	UBERON:0015488	89.93	gold quality
fallopian tube	UBERON:0003889	89.79	gold quality
islet of Langerhans	UBERON:0000006	89.24	gold quality
left ovary	UBERON:0002119	89.09	gold quality
right ovary	UBERON:0002118	89.04	gold quality
cerebellar hemisphere	UBERON:0002245	89.04	gold quality
cerebellar cortex	UBERON:0002129	88.90	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.74	gold quality
right testis	UBERON:0004534	88.40	gold quality
ovary	UBERON:0000992	88.16	gold quality
body of uterus	UBERON:0009853	88.09	gold quality
cerebellum	UBERON:0002037	88.04	gold quality
endocervix	UBERON:0000458	87.77	gold quality
testis	UBERON:0000473	87.75	gold quality
left uterine tube	UBERON:0001303	87.72	gold quality
left testis	UBERON:0004533	87.64	gold quality
muscle layer of sigmoid colon	UBERON:0035805	87.48	gold quality
mucosa of transverse colon	UBERON:0004991	87.44	gold quality
lymph node	UBERON:0000029	87.35	gold quality
spleen	UBERON:0002106	87.16	gold quality
lower esophagus muscularis layer	UBERON:0035833	87.04	gold quality
lower esophagus	UBERON:0013473	87.03	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.03

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

72 targeting NCOA5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-510-3P	99.54	70.06	2965

Literature-anchored findings (GeneRIF, showing 10)

• gene polymorphism confers susceptibility to psoriasis in a Southern European population (PMID:21645569)
• suggest that NCOA5 is a haploinsufficient tumor suppressor and that NCOA5 deficiency increases susceptibility to both glucose intolerance and HCC, partially by increasing IL-6 expression (PMID:24332041)
• NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma. (PMID:25416054)
• This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored. (PMID:27847318)
• knockout of NCOA5 can suppress the epithelial - mesenchymal transition (EMT) in hepatocellular carcinoma cells. (PMID:29626478)
• Results found the expression levels of NCOA5 mRNA and protein significantly decreased in cervical cancer (CC) tissues and correlated with poor overall survival. Its upregulation might suppress cancer cell proliferation, migration, and invasion by inactivating NOTCH3 signaling pathway. These findings suggest that NCOA5 acts as a tumor suppressor and represents a potential novel prognostic marker for overall survival in CC. (PMID:30335900)
• Nuclear Receptor Coactivator 5 is Correlated with Progression in Breast Carcinoma. (PMID:33573580)
• Analysis of Nuclear Receptor Coactivator 5 (NCOA5) Messenger RNA Expression and rs2903908 Single Nucleotide Polymorphism of NCOA5 in an Egyptian Cohort with Behcet’s Disease: A Single-Center Case-control Study. (PMID:34255592)
• NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. (PMID:37734594)
• Could NCOA5 a novel candidate gene for multiple sclerosis susceptibility? (PMID:37817021)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ncoa5	ENSDARG00000016345
mus_musculus	Ncoa5	ENSMUSG00000039804
rattus_norvegicus	Ncoa5	ENSRNOG00000017824
drosophila_melanogaster	Neos	FBGN0024542

Protein

Protein identifiers

Nuclear receptor coactivator 5 — Q9HCD5 (reviewed: Q9HCD5)

Alternative names: Coactivator independent of AF-2

All UniProt accessions (2): Q9HCD5, Q5JY17

UniProt curated annotations — full annotation on UniProt →

Function. Nuclear receptor coregulator that can have both coactivator and corepressor functions. Interacts with nuclear receptors for steroids (ESR1 and ESR2) independently of the steroid binding domain (AF-2) of the ESR receptors, and with the orphan nuclear receptor NR1D2. Involved in the coactivation of nuclear steroid receptors (ER) as well as the corepression of MYC in response to 17-beta-estradiol (E2).

Subunit / interactions. Binds HTATIP2/TIP30. Interacts with YLPM1. Forms a complex with ILF2, ILF3, YLPM1, KHDRBS1, RBMX and PPP1CA.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed.

Domain organisation. Contains one Leu-Xaa-Xaa-Leu-Leu (LxxLL) motif that is essential for the association with nuclear receptors.

RefSeq proteins (5): NP_001335077, NP_001335078, NP_001335079, NP_001335080, NP_066018* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR036621	Anticodon-bd_dom_sf	Homologous_superfamily
IPR052600	Nuc_rcpt_coact/corep	Family

UniProt features (49 total): modified residue 16, region of interest 7, compositionally biased region 7, strand 7, helix 6, mutagenesis site 2, chain 1, sequence variant 1, turn 1, short sequence motif 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
2J7Y	X-RAY DIFFRACTION	1.8
2J7X	X-RAY DIFFRACTION	2.1
4ZI1	X-RAY DIFFRACTION	2.1
1V95	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCD5-F1	59.36	0.11

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (16): 1, 3, 9, 21, 24, 29, 34, 96, 116, 126, 143, 151, 274, 378, 379, 381

Mutagenesis-validated functional residues (2):

Position	Phenotype
342	abolishes e2-inducible strong interaction with esr1, but not basal interaction.
348–349	abolishes interaction with esr1.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 150 (showing top): GGGACCA_MIR133A_MIR133B, RNGTGGGC_UNKNOWN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, TGCGCANK_UNKNOWN, CMYB_01, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, GCM_ZNF198, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GGCNKCCATNK_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, EFC_Q6, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, MARTINEZ_RB1_TARGETS_DN, GOBP_RESPONSE_TO_INSULIN, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), insulin receptor signaling pathway (GO:0008286), regulation of signal transduction (GO:0009966), glucose homeostasis (GO:0042593), negative regulation of insulin receptor signaling pathway (GO:0046627)

GO Molecular Function (4): chromatin binding (GO:0003682), transcription corepressor activity (GO:0003714), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), nucleoplasm (GO:0005654), actin cytoskeleton (GO:0015629), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of DNA-templated transcription	2
binding	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
cell surface receptor protein tyrosine kinase signaling pathway	1
cellular response to insulin stimulus	1
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
carbohydrate homeostasis	1
insulin receptor signaling pathway	1
negative regulation of signal transduction	1
regulation of insulin receptor signaling pathway	1
negative regulation of cellular response to insulin stimulus	1
transcription coregulator activity	1
nucleic acid binding	1
nuclear lumen	1
cellular anatomical structure	1
cytoskeleton	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2191 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NCOA5	ESR2	Q92731	642
NCOA5	NUP50	Q9UKX7	538
NCOA5	CDH22	Q9UJ99	509
NCOA5	NUP98	P52948	475
NCOA5	CIMIP1	Q9H1P6	450
NCOA5	NPEPL1	Q8NDH3	448
NCOA5	WDR26	Q9H7D7	421
NCOA5	YAE1	Q9NRH1	409
NCOA5	BLZF1	Q9H2G9	406
NCOA5	DCXR	Q7Z4W1	393
NCOA5	GLG1	Q92896	388
NCOA5	ZC3H4	Q9UPT8	359
NCOA5	NR2C2AP	Q86WQ0	353
NCOA5	MMD	Q15546	350
NCOA5	TMEM94	Q12767	348

IntAct

103 interactions, top by confidence:

A	B	Type	Score
PAIP1	PABPC1	psi-mi:“MI:0914”(association)	0.970
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
KHDRBS2	KHDRBS3	psi-mi:“MI:0914”(association)	0.800
ILF3	ADAR	psi-mi:“MI:0914”(association)	0.640
NCOA5	NCOA5	psi-mi:“MI:0915”(physical association)	0.550
LRRC4C	DVL2	psi-mi:“MI:0914”(association)	0.530
RBMX	PTCD1	psi-mi:“MI:0914”(association)	0.530
SYNGAP1	SEC16A	psi-mi:“MI:0914”(association)	0.530
SNRPC	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
Nr1d2	NCOA5	psi-mi:“MI:0915”(physical association)	0.510
CPSF6	DDX39A	psi-mi:“MI:0914”(association)	0.480
PTBP3	HNRNPC	psi-mi:“MI:0914”(association)	0.480
NCOA5	AIFM1	psi-mi:“MI:0915”(physical association)	0.400
NCOA5	GALC	psi-mi:“MI:0915”(physical association)	0.400
NCOA5	ESR1	psi-mi:“MI:0915”(physical association)	0.400
NCOA5	NTAQ1	psi-mi:“MI:0915”(physical association)	0.370
NCOA5	rep	psi-mi:“MI:0915”(physical association)	0.370
CDC37	NCOA5	psi-mi:“MI:0915”(physical association)	0.370
TSC22D1	NCOA5	psi-mi:“MI:0915”(physical association)	0.370
Taf15	BTBD10	psi-mi:“MI:0914”(association)	0.350
MPHOSPH8	HCFC1	psi-mi:“MI:0914”(association)	0.350
MATR3	BCLAF3	psi-mi:“MI:0914”(association)	0.350
HNRNPA1	MATR3	psi-mi:“MI:0914”(association)	0.350
TWNK	RAD9A	psi-mi:“MI:0914”(association)	0.350
Fus	DDX3X	psi-mi:“MI:0914”(association)	0.350

BioGRID (168): NCOA5 (Two-hybrid), NCOA5 (Two-hybrid), NCOA5 (Two-hybrid), SYT16 (Two-hybrid), KHDRBS2 (Two-hybrid), NCOA5 (Affinity Capture-RNA), NCOA5 (Affinity Capture-RNA), NCOA5 (Affinity Capture-MS), NCOA5 (Affinity Capture-MS), NCOA5 (Affinity Capture-MS), NCOA5 (Affinity Capture-MS), AMZ2 (Affinity Capture-MS), GALC (Affinity Capture-MS), NCOA5 (Affinity Capture-MS), NCOA5 (Proximity Label-MS)

ESM2 similar proteins: A0A8M2, A0JMU8, A1L1K8, A5D7H5, B9DFV2, E1BUG7, F4JP52, G1SW77, G3X9Z4, O08719, O15234, O94913, Q0V898, Q1LVV0, Q2T9I5, Q32NW2, Q3MHF8, Q498K9, Q566L7, Q5CZI8, Q5JVS0, Q5R4R4, Q5T8P6, Q5TYQ8, Q659C4, Q68FI1, Q6AXS5, Q6NVR8, Q6NZN0, Q6PKG0, Q8AVJ2, Q8CGC4, Q8K2F8, Q8K3W3, Q8K3X0, Q8NC51, Q8ND56, Q91W18, Q91W39, Q96D71

Diamond homologs: Q91W39, Q9HCD5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 137 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA Polymerase II Transcription Termination	9	23.5×	2e-08
Transport of Mature Transcript to Cytoplasm	5	22.7×	9e-05
mRNA 3’-end processing	9	21.1×	3e-08
mRNA Polyadenylation	15	15.7×	9e-12
mRNA Splicing	10	13.1×	3e-07
Processing of Capped Intron-Containing Pre-mRNA	13	12.7×	4e-09
Transport of Mature mRNA derived from an Intron-Containing Transcript	6	10.9×	5e-04
mRNA Splicing - Major Pathway	13	8.5×	3e-07

GO biological processes:

GO term	Partners	Fold	FDR
regulation of alternative mRNA splicing, via spliceosome	12	24.8×	4e-11
activation of innate immune response	5	20.4×	4e-04
mitophagy	5	13.5×	2e-03
regulation of RNA splicing	7	13.0×	1e-04
mRNA splicing, via spliceosome	14	10.9×	2e-08
circadian regulation of gene expression	5	9.9×	8e-03
autophagosome assembly	5	9.5×	9e-03
RNA processing	5	9.3×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	95
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1196 predictions. Top by Δscore:

Variant	Effect	Δscore
20:46063354:G:C	donor_gain	1.0000
20:46063355:CTCAC:C	donor_loss	1.0000
20:46063356:TCACC:T	donor_loss	1.0000
20:46063357:CACC:C	donor_loss	1.0000
20:46063358:A:AC	donor_gain	1.0000
20:46063359:C:CA	donor_loss	1.0000
20:46063359:C:CC	donor_gain	1.0000
20:46063359:CCAGG:C	donor_gain	1.0000
20:46063676:ATGCT:A	acceptor_gain	1.0000
20:46063677:TGCT:T	acceptor_gain	1.0000
20:46063678:GCT:G	acceptor_gain	1.0000
20:46063679:CT:C	acceptor_gain	1.0000
20:46063679:CTC:C	acceptor_gain	1.0000
20:46063680:TCT:T	acceptor_gain	1.0000
20:46063681:C:A	acceptor_gain	1.0000
20:46063681:C:CC	acceptor_gain	1.0000
20:46063683:G:C	acceptor_gain	1.0000
20:46065116:C:A	donor_gain	1.0000
20:46065227:CT:C	acceptor_gain	1.0000
20:46065229:C:CC	acceptor_gain	1.0000
20:46067050:CTTAC:C	donor_loss	1.0000
20:46067051:TTA:T	donor_loss	1.0000
20:46067052:TACT:T	donor_loss	1.0000
20:46067053:A:AC	donor_gain	1.0000
20:46067053:ACTTT:A	donor_loss	1.0000
20:46067054:C:CA	donor_gain	1.0000
20:46067054:CT:C	donor_gain	1.0000
20:46067177:ACGCT:A	acceptor_gain	1.0000
20:46067178:CGCT:C	acceptor_gain	1.0000
20:46067178:CGCTC:C	acceptor_gain	1.0000

AlphaMissense

3796 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:46062400:A:G	L547P	1.000
20:46062409:A:G	L544P	1.000
20:46062736:A:C	I435S	1.000
20:46062736:A:G	I435T	1.000
20:46062736:A:T	I435N	1.000
20:46063410:A:G	L367P	1.000
20:46063464:A:G	L349P	1.000
20:46063467:A:G	L348P	1.000
20:46063639:C:G	A291P	1.000
20:46063644:A:G	L289P	1.000
20:46063653:G:T	A286D	1.000
20:46063654:C:G	A286P	1.000
20:46063668:A:C	M281R	1.000
20:46063668:A:G	M281T	1.000
20:46063670:G:C	N280K	1.000
20:46063670:G:T	N280K	1.000
20:46063671:T:A	N280I	1.000
20:46063674:C:A	R279L	1.000
20:46063674:C:G	R279P	1.000
20:46063675:G:C	R279G	1.000
20:46063675:G:T	R279S	1.000
20:46063676:A:C	H278Q	1.000
20:46063676:A:T	H278Q	1.000
20:46063677:T:C	H278R	1.000
20:46063677:T:G	H278P	1.000
20:46063678:G:C	H278D	1.000
20:46063678:G:T	H278N	1.000
20:46063679:C:A	E277D	1.000
20:46063679:C:G	E277D	1.000
20:46065049:A:C	I270S	1.000

dbSNP variants (sampled 300 via entrez): RS1000054566 (20:46072506 G>A), RS1000101064 (20:46074500 T>G), RS1000196533 (20:46085070 G>A,T), RS1000210951 (20:46088111 C>T), RS1000211537 (20:46078049 G>A), RS1000237187 (20:46083557 G>A), RS1000274514 (20:46066589 G>A), RS1000353873 (20:46089808 G>A), RS1000444715 (20:46078367 C>A), RS1000501159 (20:46082011 T>G), RS1000532312 (20:46083290 T>C), RS1000701941 (20:46075735 A>G), RS1000806092 (20:46089289 G>A,C), RS1001093141 (20:46089126 C>T), RS1001111809 (20:46088464 G>C)

Disease associations

OMIM: gene MIM:616825 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001198_64	Multiple sclerosis	5.000000e-10
GCST003995_12	Tonsillectomy	7.000000e-12
GCST004131_122	Inflammatory bowel disease	2.000000e-06
GCST004132_43	Crohn’s disease	2.000000e-07
GCST005014_178	Tonsillectomy	7.000000e-12
GCST005752_163	Systemic lupus erythematosus	1.000000e-08
GCST007062_6	Hodgkin’s lymphoma	2.000000e-08
GCST007400_68	Systemic lupus erythematosus	1.000000e-07
GCST008718_2	Follicular lymphoma or multiple sclerosis	1.000000e-07
GCST008722_4	Diffuse large B-cell lymphoma or multiple sclerosis	5.000000e-09
GCST008723_6	Marginal zone lymphoma or multiple sclerosis	1.000000e-07
GCST009597_22	Multiple sclerosis	5.000000e-19
GCST010242_228	HDL cholesterol levels	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007924	tonsillectomy risk measurement
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	4
Rotenone	increases expression, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
deoxynivalenol	increases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
ferrous chloride	decreases expression	1
coumarin	affects phosphorylation	1
avobenzone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Leflunomide	decreases expression	1
Atrazine	decreases expression	1
Caffeine	affects phosphorylation	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Niclosamide	decreases expression	1
Oxygen	decreases expression	1
Ribonucleotides	affects binding	1
Tetrachlorodibenzodioxin	affects expression	1
1-Methyl-4-phenylpyridinium	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1NZ	Abcam K-562 NCOA5 KO	Cancer cell line	Female
CVCL_D2KJ	Abcam Raji NCOA5 KO	Cancer cell line	Male
CVCL_WQ01	Abcam Jurkat NCOA5 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.